Lumateperone, an Antipsychotic, is Tested in a Phase 3 Trial for Major Depressive Episodes in Bipolar I and II Disorders
An international team of researchers has reported positive results in a phase 3 clinical trial of a drug to treat depressive episodes in patients with bipolar I and bipolar II disorder. Read More
Study Links Schizophrenia Medicines’ Anticholinergic Impact to Risk of Cognitive Impairment
An important study led by BBRF grantees has closely examined a commonplace pharmacologic property of many antipsychotic and other medications commonly prescribed to people with chronic schizophrenia… Read More
Combining the Antipsychotic Olanzapine with an Opioid-Receptor Blocker Significantly Limited Weight-Gain Risk in Schizophrenia Patients
A clinical trial involving over 500 adults diagnosed with schizophrenia has found that by adding the drug samidorphan to the antipsychotic medicine olanzapine, it was possible to substantially reduce… Read More
Drugs Targeting the Glutamate System Warrant Continued Development for Schizophrenia, Study Finds
In the continuing effort to develop new medicines to treat schizophrenia, a team led by BBRF Scientific Council member Jeffrey Lieberman, M.D., and including nine other Council Members, BBRF grantees… Read More
Study Finds Changes in the Treatment of Bipolar Disorder Over 20 Years
A study covering the 20 years between 1997 and 2016 shows that substantial changes have occurred in the way doctors are treating outpatients diagnosed with bipolar disorder. Among a number of… Read More